Literature DB >> 24510891

Newcastle disease virus-like particles: preparation, purification, quantification, and incorporation of foreign glycoproteins.

Lori W McGinnes1, Trudy G Morrison1,2.   

Abstract

Virus-like particles (VLPs) are large particles, the size of viruses, composed of repeating structures that mimic those of infectious virus. Since their structures are similar to that of viruses, they have been used to study the mechanisms of virus assembly. They are also in development for delivery of molecules to cells and in studies of the immunogenicity of particle-associated antigens. However, they have been most widely used for development of vaccines and vaccine candidates. VLPs can form upon the expression of the structural proteins of many different viruses. This chapter describes the generation and purification of VLPs formed with the structural proteins, M, NP, F, and HN proteins, of Newcastle disease virus (NDV). Newcastle disease virus-like particles (ND VLPs) have also been developed as a platform for assembly into VLPs of glycoproteins from other viruses. This chapter describes the methods for this use of ND VLPs.
Copyright © 2013 John Wiley & Sons, Inc.

Entities:  

Keywords:  Newcastle disease virus; chimera glycoproteins; paramyxovirus; virus-like particles

Mesh:

Substances:

Year:  2013        PMID: 24510891      PMCID: PMC4036627          DOI: 10.1002/9780471729259.mc1802s30

Source DB:  PubMed          Journal:  Curr Protoc Microbiol


  29 in total

Review 1.  Virus-like particles as immunogens.

Authors:  Rob Noad; Polly Roy
Journal:  Trends Microbiol       Date:  2003-09       Impact factor: 17.079

2.  Requirements for the assembly and release of Newcastle disease virus-like particles.

Authors:  Homer D Pantua; Lori W McGinnes; Mark E Peeples; Trudy G Morrison
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 3.  The coming of age of virus-like particle vaccines.

Authors:  Gary T Jennings; Martin F Bachmann
Journal:  Biol Chem       Date:  2008-05       Impact factor: 3.915

4.  Requirements for budding of paramyxovirus simian virus 5 virus-like particles.

Authors:  Anthony P Schmitt; George P Leser; David L Waning; Robert A Lamb
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Role of matrix and fusion proteins in budding of Sendai virus.

Authors:  T Takimoto; K G Murti; T Bousse; R A Scroggs; A Portner
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

7.  Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope.

Authors:  Jean-Rémy Sadeyen; Sylvie Tourne; Marina Shkreli; Pierre-Yves Sizaret; Pierre Coursaget
Journal:  Virology       Date:  2003-04-25       Impact factor: 3.616

Review 8.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

9.  Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles.

Authors:  Ming Li; Phuong Tieu Schmitt; Zhuo Li; Thomas S McCrory; Biao He; Anthony P Schmitt
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

10.  Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.

Authors:  Joel R Haynes; Leslie Dokken; James A Wiley; Andrew G Cawthon; John Bigger; Allen G Harmsen; Charles Richardson
Journal:  Vaccine       Date:  2008-11-19       Impact factor: 3.641

View more
  14 in total

1.  Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Sarah A Kenward; Robert T Woodland; Trudy G Morrison
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

2.  Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Trudy G Morrison
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

3.  Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.

Authors:  Jorge C G Blanco; Lurds R Fernando; Wei Zhang; Arash Kamali; Marina S Boukhvalova; Lori McGinnes-Cullen; Trudy G Morrison
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

4.  A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.

Authors:  Javier Gordon Ogembo; Matthew R Muraswki; Lori W McGinnes; Agapi Parcharidou; Rujapak Sutiwisesak; Timelia Tison; Juan Avendano; Deep Agnani; Robert W Finberg; Trudy G Morrison; Joyce D Fingeroth
Journal:  J Transl Med       Date:  2015-02-06       Impact factor: 5.531

5.  The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV.

Authors:  Lori M Cullen; Madelyn R Schmidt; Trudy G Morrison
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

6.  BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.

Authors:  Anne K Barasa; Peng Ye; Meredith Phelps; Ganapathiram T Arivudainambi; Timelia Tison; Javier Gordon Ogembo
Journal:  Oncotarget       Date:  2017-05-23

7.  Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.

Authors:  Elizabeth M Perez; Joslyn Foley; Timelia Tison; Rute Silva; Javier Gordon Ogembo
Journal:  Oncotarget       Date:  2017-03-21

8.  MiR-375 Has Contrasting Effects on Newcastle Disease Virus Growth Depending on the Target Gene.

Authors:  Xinglong Wang; Yanqing Jia; Xiangwei Wang; Chongyang Wang; Changjie Lv; Xiaoqin Li; Zhili Chu; Qingsong Han; Sa Xiao; Shuxia Zhang; Zengqi Yang
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

9.  Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.

Authors:  Lori McGinnes Cullen; Jorge C G Blanco; Trudy G Morrison
Journal:  J Transl Med       Date:  2015-11-05       Impact factor: 5.531

10.  Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model.

Authors:  Jorge C G Blanco; Lioubov M Pletneva; Lori McGinnes-Cullen; Raymonde O Otoa; Mira C Patel; Lurds R Fernando; Marina S Boukhvalova; Trudy G Morrison
Journal:  Nat Commun       Date:  2018-05-15       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.